SupremeToday Landscape Ad
Back
Next
Headnote Court Copy Facts Arguments Court observation Judicial Analysis Case Map Category Hierarchy Table of Content
Listen Article Pause Article
judgment-img

2026 Supreme(Online)(Del) 37831

IN THE HIGH COURT OF DELHI AT NEW DELHI


CNR No. DLHC010774392025


CS(COMM) 1087/2025, I.A. 25149/2025


MODI-MUNDIPHARMA PVT. LTD. .....Plaintiff


Through: Ms. Prachi Aggarwal and Ms. Medha Singh, Advocates.


versus


ARLAK BIOTECH PRIVATE LIMITED & ANR. .....Defendants


Through:


CORAM: HON'BLE MR. JUSTICE VIKAS MAHAJAN


VIKAS MAHAJAN, J


NOVEMBER 4, 2026/jg/sj

O R D E R

% 04.11.2026

I.A. 30624/2026 (by plaintiff under Order XIII-A read with Order VIII Rule 10 read with Section 151 CPC, 1908)

1. The present suit has been filed by the plaintiff praying for a decree of permanent injunction restraining the infringement of plaintiff’s trade marks, copyright, dilution, tarnishment, passing off, rendition of accounts, damages, etc.

2. The suit has been filed by the plaintiff against the defendants in respect of nitroglycerin-controlled release tablets being marketed and manufactured under the impugned mark “Z-CONTIN”.

3. The case set out in the plaint is that the plaintiff is the registered proprietor of the mark “NITROCONTIN”in Class 5 and holds more than 80 registrations in the same class for pharmaceutical products bearing “CONTIN”as acommon feature (hereinafter referred to as “CONTIN series of trademarks”). Some of the registrations which have been obtained by the plaintiff have been given in paragraph 7 of the plaint and the same are also set out hereinbelow:

4. Likewise, it has also been averred in paragraph 9 of the plaint that the plaintiff holds the registration of the mark “NITROCONTIN” in Hindi language and holds registration of the trade dress “NITROCONTIN® 2.6” and “NITROCONTIN® 6.4”. The relevant extract from paragraph 9 has been set out hereinbelow:

5. It is stated in the plaint that the aforesaid registrations in favour of the plaintiff are valid and subsisting. The art work, label and trade dress of the plaintiff’s “CONTIN series of trademarks”, including “NITROCONTIN” further constitutes original artistic work, in which the plaintiff is the first owner of copyright under Section 17 of the Copyright Act, 1957.

6. It is further stated that no third party holds any registration in Class 5 using “CONTIN” as a suffix.

7. It is stated that the plaintiff’s series of marks having the dominant part “CONTIN” have acquired an impeccable goodwill and reputation which can be gauged from the turnover of the plaintiff, which has been detailed in paragraphs 13 and 16 of the plaint, and has been extracted hereinbelow:

8. It is submitted that the plaintiff has also invested huge sums of money and efforts in relation to the promotional activities and publicity concerning their products sold under the “CONTIN series of trademarks”. The advertisement and promotional expenses have been given in the form of a tabulated chart in paragraphs 14 and 17 of the plaint, which have been set out hereinbelow:

9. Ms. Prachi Aggarwal, learned counsel appearing for the plaintiff, submits that the plaintiff has been vigilant in enforcing its rights in the “CONTIN series of trademarks” and number of orders have been passed in its favour restraining different defendants in various suits. The attention of the Court has been invited to paragraph 22 of the plaint, wherein the details of the orders obtained by the plaintiff in various suits have been set out.

10. It is stated in the plaint that defendant no.1, while operating through its division Soigner Pharma, in turn has a further division Cardiac Vintage, which is engaged in the business of pharmaceutical products and marketing of the infringing product “Z-CONTIN”. Defendant no.2 is stated to be the manufacturer of the said product. The defendants have no association whatsoever with the plaintiff.

11. It is submitted that in May, 2025, the plaintiff came across the defendants’ nitroglycerin-controlled release tablets of 2.6 mg being sold under the impugned mark “Z-CONTIN” on IndiaMart and in physical stores across India. In support of her submission, she has invited the attention of the Court to pages 638 to 644 of the plaintiff’s documents. The relevant portion of the said pages has been set out hereinbelow for the ease of reference:

12. It is averred that upon further examination of the defendants’ product, the plaintiff found that the said mark was being used for the same formulation as their NITROCONTIN® product i.e. nitroglycerin tablets 2.6m

1
2
3
4
5
6
7
8
9
10
11
SupremeToday Portrait Ad
supreme today icon
whatsapp-icon Back to top